A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.


Journal Article

Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams. To address the feasibility and efficacy of using a pediatric treatment regimen for AYA patients with newly diagnosed ALL administered by adult treatment teams, we performed a prospective study, CALGB 10403, with doses and schedule identical to those in the Children's Oncology Group study AALL0232. From 2007 to 2012, 318 patients were enrolled; 295 were eligible and evaluable for response. Median age was 24 years (range, 17-39 years). Use of the pediatric regimen was safe; overall treatment-related mortality was 3%, and there were only 2 postremission deaths. Median event-free survival (EFS) was 78.1 months (95% confidence interval [CI], 41.8 to not reached), more than double the historical control of 30 months (95% CI, 22-38 months); 3-year EFS was 59% (95% CI, 54%-65%). Median overall survival (OS) was not reached. Estimated 3-year OS was 73% (95% CI, 68%-78%). Pretreatment risk factors associated with worse treatment outcomes included obesity and presence of the Philadelphia-like gene expression signature. Use of a pediatric regimen for AYAs with ALL up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls. CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL. This trial was registered at www.clinicaltrials.gov as #NCT00558519.

Full Text

Duke Authors

Cited Authors

  • Stock, W; Luger, SM; Advani, AS; Yin, J; Harvey, RC; Mullighan, CG; Willman, CL; Fulton, N; Laumann, KM; Malnassy, G; Paietta, E; Parker, E; Geyer, S; Mrózek, K; Bloomfield, CD; Sanford, B; Marcucci, G; Liedtke, M; Claxton, DF; Foster, MC; Bogart, JA; Grecula, JC; Appelbaum, FR; Erba, H; Litzow, MR; Tallman, MS; Stone, RM; Larson, RA

Published Date

  • April 4, 2019

Published In

Volume / Issue

  • 133 / 14

Start / End Page

  • 1548 - 1559

PubMed ID

  • 30658992

Pubmed Central ID

  • 30658992

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2018-10-881961


  • eng

Conference Location

  • United States